Published: Fri, November 04, 2016
Economy | By Melissa Porter

RBC Capital Markets Reaffirmed "Buy" Rating for Zimmer Biomet Holdings Inc. (ZBH)

RBC Capital Markets Reaffirmed

(NYSE:ZBH) latest quarter ended on 30 Jun 2016, company revealed earnings of $2.02 a share. Canaccord Genuity maintained it with "Buy" rating and $150 target price in Friday, September 4 report.

By looking at the Recommendation Trends of the stock polled by Thomson First call for the current month, 10 Analysts assigned the stock as Strong Buy.

Several other equities research analysts have also recently issued reports on ZBH. They set a "buy" rating and a $155.00 price target on the stock. The stock is going forward its 52-week low with 25.38% and moving down from its 52-week high price with -33.74%. (NYSE:ZBH) now has P/E (Price to Earnings) ratio of 110.19 while the company's industry has 34.57 P/E and the sector P/E is 33.51. Similarly, 16 of 23 analysts rate ZBH a "buy" or better, compared to seven "hold" opinions and not a single "sell". Zimmer Biomet Holdings presently has a consensus rating of "Buy" and an average price target of $130.81. The stock exchanged hands with 19.19 million shares contrast to its average daily volume of 22.43 million shares. It also lowered the high end of its earnings expectations for the year.

Market capitalization is the total market value of all of a company's outstanding shares. The average numbers of shares are traded in a security per day, during the recent 3-month period.

The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) gapped down by $11.92 today and has $100.41 target or 5.00% below today's $105.69 share price.

However, the full-year revenue guidance was updated to between $7.63 billion and $7.65 billion with the full year growth estimated at 1.65 percent to 1.9 percent instead of the previously expected 2.5 percent to 3 percent; the new earnings per share estimation was revised to $1.50 to $1.60, compared to $1.50 to $1.75 that was previously reported.

In case of Revenue Estimates, 21 analysts have provided their consensus Average Revenue Estimates for Zimmer Biomet Holdings, 1.84 Billion. Equities research analysts forecast that Zimmer Biomet Holdings will post $7.97 EPS for the current year. Co declared a dividend for shareholders paid on Friday the 28th of October 2016.

The Warsaw, Ind. -based maker of orthopedic devices said it now sees diluted earnings at $1.50 to $1.60 a share, down from its previous forecast of $1.50 to $1.75. The ex-dividend date of this dividend was Wednesday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.78%. Zimmer Biomet Holdings's dividend payout ratio (DPR) is presently 157.38%. The shares were sold at an average price of $129.16, for a total transaction of $166,228.92. Adage Capital Partners GP L.L.C. now owns 894,005 shares of the company's stock worth $95,328,000 after buying an additional 238,107 shares during the last quarter. The disclosure for this sale can be found here. The present market cap reflects only on the equity of NYSE:ZBH Medical Appliances & Equipment and is vital to note that the firm's choice of capital structure holds a substantial impact on how the aggregate value of the company allocated within the equity and debt.

Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products; sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. Global X Management Co.

Large investors have recently bought and sold shares of the company.

Like this: